Claudia Vener

1.7k total citations
43 papers, 899 citations indexed

About

Claudia Vener is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Claudia Vener has authored 43 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 13 papers in Hematology and 11 papers in Oncology. Recurrent topics in Claudia Vener's work include Lymphoma Diagnosis and Treatment (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Claudia Vener is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Claudia Vener collaborates with scholars based in Italy, France and Spain. Claudia Vener's co-authors include Umberto Gianelli, Giorgio La Nasa, Alessandra Iurlo, Federica Savi, Milena Sant, Nicola Stefano Fracchiolla, Franca Radaelli, Silvano Bòsari, Alessia Moro and Gabriella Pravettoni and has published in prestigious journals such as Blood, PLoS ONE and American Journal of Epidemiology.

In The Last Decade

Claudia Vener

40 papers receiving 883 citations

Peers

Countries citing papers authored by Claudia Vener

Since Specialization

Citations

This map shows the geographic impact of Claudia Vener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Vener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Vener more than expected).

Fields of papers citing papers by Claudia Vener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Vener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Vener. The network helps show where Claudia Vener may publish in the future.

Co-authorship network of co-authors of Claudia Vener

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Vener. A scholar is included among the top collaborators of Claudia Vener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Vener. Claudia Vener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000–2013: Results from EUROCARE-6, a population-based study 2025 ·European Journal of Cancer ·Annalisa Trama, (unknown), Elena Demuru, Roberta De Angelis, (unknown), X. Troussard, Damien Bennett, Rafael Marcos‐Gragera, Claudia E. Kuehni, Huan Liu, Anna Bernasconi, Claudia Vener, Marcela Guevara, C. Michel Zwaan, A. Mayer-da-Silva, Keiu Paapsi, Rosalia Ragusa, (unknown)	0
2	Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study 2025 ·European Journal of Cancer ·Emanuele Crocetti, Damien Bennett, Valérie Jooste, Silvia Rossi, Luigino Dal Maso, Rafael Marcos‐Gragera, Stephanie Smits, Tina Žagar, Xavier Troussard, (unknown), Laëtitia Daubisse‐Marliac, (unknown), Alexander Katalinic, María‐José Sánchez, Claudia Vener, Seyed Mohsen Mousavi, (unknown), (unknown)	1
3	The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation 2025 ·American Journal of Epidemiology ·Laura Botta, Riccardo Capocaccia, Alice Bernasconi, Silvia Rossi, Jaume Galcerán, Luigino Dal Maso, Côme Lepage, Florence Molinié, Anne‐Marie Bouvier, Rafael Marcos‐Gragera, Claudia Vener, Marcela Guevara, Deirdre M. Murray, Rosalia Ragusa, Gemma Gatta, Valérie Jooste, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
4	Advanced glycation end products and breast cancer risk in a sample of the ORDET cohort 2025 ·The International Journal of Biological Markers ·Claudia Agnoli, (unknown), (unknown), (unknown), Claudia Vener, Pierluigi Mauri, Antonella De Palma, Elisabetta Venturelli, Sabina Sieri	1
5	Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe 2025 ·European Journal of Cancer ·Laura Botta, Riccardo Capocaccia, Claudia Vener, Alice Bernasconi, Annalisa Trama, (unknown), Elena Demuru, Roberta De Angelis, Silvia Rossi, Seyed Mohsen Mousavi, Frederik Peters, (unknown), (unknown), Valérie Jooste	2
6	Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers 2024 ·European Journal of Cancer ·Laura Botta, Riccardo Capocaccia, Alice Bernasconi, Silvia Rossi, Jaume Galcerán, Luigino Dal Maso, Côme Lepage, Florence Molinié, Anne‐Marie Bouvier, Rafael Marcos‐Gragera, Claudia Vener, Marcela Guevara, Deirdre M. Murray, Rosalia Ragusa, Gemma Gatta, Valérie Jooste	4
7	Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020 2023 ·Frontiers in Oncology ·Lucìa Mangone, Domenico Penna, (unknown), (unknown), (unknown), Francesco Merli, (unknown), Barbara Gamberi, Alessia Tieghi, Riccardo Valli, (unknown), Mauro Iori, Paolo Giorgi Rossi, Claudia Vener, Fortunato Morabito, Antonino Neri, Stefano Luminari	3
8	Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers 2022 ·Frontiers in Oncology ·Annalisa Trama, Claudia Vener, Paolo Lasalvia, Alice Bernasconi, (unknown)	2
9	Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients 2022 ·Patient Preference and Adherence ·Ilaria Cutica, Silvia Riva, Ester Orlandi, Alessandra Iurlo, Claudia Vener, Chiara Elena, Cristina Bucelli, Daniele Cattaneo, (unknown), Gabriella Pravettoni	1
10	The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars 2021 ·Frontiers in Psychology ·Davide Mazzoni, Claudia Vener, Ketti Mazzocco, Dario Monzani, Gabriella Pravettoni	4
11	Epidemiology, management and outcome of status epilepticus in adults: single-center Italian survey 2021 ·Neurological Sciences ·Carlotta Mutti, Angelo Sansonetti, (unknown), Claudia Vener, Irene Florindo, Anna Elisabetta Vaudano, (unknown), (unknown), Liborio Parrino, (unknown)	1
12	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis 2020 ·Blood Advances ·Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant	81
13	Presepsin (Soluble CD14 Subtype): Reference Ranges of a New Sepsis Marker in Term and Preterm Neonates 2015 ·PLoS ONE ·Lorenza Pugni, Carlo Pietrasanta, Silvano Milani, Claudia Vener, Andrea Ronchi, (unknown), Milena Arghittu, Fabio Mosca	54
14	Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms 2011 ·Journal of Clinical Pathology ·Leonardo Boiocchi, Claudia Vener, Federica Savi, Emanuela Bonoldi, Alessia Moro, Nicola Stefano Fracchiolla, Alessandra Iurlo, Giorgio La Nasa, Guido Coggi, Silvano Bòsari, Umberto Gianelli	21
15	Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT 2010 ·Bone Marrow Transplantation ·Mauro Viganò, Claudia Vener, Pietro Lampertico, C. Annaloro, Christian Pichoud, Fabien Zoulim, F. Facchetti, Francesca Poli, M. Scalamogna, G Lambertenghi Deliliers, Massimo Colombo	67
16	The Significance of Bone Marrow Biopsy andJAK2^V617FMutation in the Differential Diagnosis Between the “Early” Prepolycythemic Phase of Polycythemia Vera and Essential Thrombocythemia 2008 ·American Journal of Clinical Pathology ·Umberto Gianelli, Alessandra Iurlo, Claudia Vener, Alessia Moro, Elisa Fermo, Paola Bianchi, Daniela Graziani, Franca Radaelli, Guido Coggi, Silvano Bòsari, Giorgio La Nasa, Alberto Zanella	50
17	Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome 2007 ·Bone Marrow Transplantation ·Francesco Onida, Giorgia Saporiti, Emilio Berti, A. Della Volpe, C. Annaloro, (unknown), Elena Tagliaferri, Claudia Vener, Pamela Vezzoli, Alessandro Rambaldi, Benedetto Bruno, Giorgio La Nasa	1
18	Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis 2007 ·Blood ·Claudia Vener, Nicola Stefano Fracchiolla, Umberto Gianelli, Rossella Calori, Franca Radaelli, Alessandra Iurlo, Sabrina Caberlon, Giancarla Gerli, Leonardo Boiocchi, Giorgio La Nasa	61
19	Low dose campath 1-H is highly effective and safe in advanced chronic CLL 2006 ·Haematologica ·Agostino Cortelezzi, (unknown), Umberto Gianelli, Barbara Sarina, Claudia Vener, Gianluigi Reda, Francesco Ripamonti, Lino Nobili, Giorgio La Nasa	1
20	ZAP-70 immunoreactivity is a prognostic marker of diseaseprogression in chronic lymphocytic leukemia 2005 ·Leukemia & lymphoma ·Claudia Vener, Umberto Gianelli, Agostino Cortelezzi, Nicola Stefano Fracchiolla, (unknown), Federica Savi, (unknown), Silvano Bòsari, Giorgio La Nasa	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact